BriaCell’s Bria-IMT Crushes HR+ Breast Cancer Survival—17.3 Months Beats TRODELVY

April 16, 2025

DENVER, Colo., Apr 16, 2025 (247marketnews.com)- BriaCell Therapeutics (NASDAQ:BCTX) unveiled Phase 2 survival data for its Bria-IMT regimen, obliterating standards in hormone receptor positive (HR+) metastatic breast cancer (MBC). Bria-IMT delivered a median overall survival of 17.3 months in HR+ patients, trouncing TRODELVY’s 14.4 months and showcasing blockbuster potential in an estimated $30 billion breast cancer market.

Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer, stated, “HR+ and TNBC metastatic breast cancer represent a significant proportion of the patient population and are the most difficult patient groups to treat. They have limited therapeutic options and overall survival of only a few months. Our clinical data supports our hypothesis that the Bria-IMT regimen + CPI has the potential to address the unmet medical needs of HR+ and TNBC MBC patients and provide an effective and well-tolerated therapeutic option.”

In BriaCell’s Phase 2 study, 25 of 37 late-stage MBC patients treated with Bria-IMT plus checkpoint inhibitors (CPI) had HR+ breast cancer, achieving a 17.3-month median survival—a 20% edge over TRODELVY’s antibody-drug conjugate (ADC) benchmark in similar heavily pre-treated patients. For triple negative breast cancer (TNBC), Bria-IMT matched TRODELVY’s survival but soared 70% above chemotherapy baselines, a stunning win for this aggressive subtype lacking ER, PR, and HER2 receptors.

There were no Bria-IMT-related discontinuations to date, unlike ADCs’ toxicity hurdles.

The regimen, now in a pivotal Phase 3 trial, leverages personalized immunotherapy to outpace ADCs.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BCTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.